Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase I Study of KLA318-2 Nanocrystal Injection
Sponsor: Hunan Kelun Pharmaceutical Co., Ltd.
Summary
The purpose of this study is to evaluate the safety,tolerability and pharmacokinetics properties of KLA318-2 Nanocrystal Injection after a single intravenous injection in healthy participants.
Official title: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KLA318-2 Nanocrystal Injection in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2025-09-01
Completion Date
2026-05-31
Last Updated
2025-11-17
Healthy Volunteers
Yes
Conditions
Interventions
KLA318-2 Nanocrystal Injection
Intravenous injection, single dose
Celebrex Capsule
P.O., single dose
Locations (1)
The first affiliated hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
Jinan, Shandong, China